secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001193125-25-326925
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027
--------------------------------------------------------------------------------

- Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.
- Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.
- Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.
- Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/0001193125-25-326925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/d213128d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-326925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer